Lupin announces District Court Ruling on Ramipril

Lupin Ltd has announced that the United State District Court for the Eastern District of Virginia has issued an opinion following the completion of a trial on Sanofi-Aventis US Patent No. - 5061722 relating to Altace® (Ramipril) and found the patent to be valid.

Commenting on the judgment, Dr. Kamal Sharma, Managing Director of the Company said "It was a very close call for us and we are disappointed that the Court found the patent to be valid, albeit reluctantly, in the judge own words. We intend to appeal this decision to the Federal Circuit."

The court decision arises from a suit filed by King Pharmaceuticals and Sanofi-Aventis against the Company alleging patent infringement on the 5061722 patent listed in the FDA´s Orange Book. The trial was completed in June 2006.

Source : Equity Bulls

Keywords